Qilu Pharmaceutical, Mabpharm, Bio-Thera Solutions

Henlius, Innovent Biologics, Bio-Thera Solutions

No foreign companies have received biosimilar approvals from Chinese regulators, although some are trying. Rapid growth of the Chinese biologics market and its potential size are luring them in. The biologics market stood at $40 billion in 2018, and Goodwin Procter has anticipated a $99 billion biologics trade in China by 2023. Henlius, Qilu Pharmaceutical, Bio-Thera Solutions, and Zhejiang Hisun together account for all 9 biosimilar approvals thus far. 

For a table depicting biosimilar approvals and development projects in China, click 

Polls

Business & Practice

Regulatory

News

Test your knowledge of biosimilar approvals in China.

Poll: How Much Do You Know About Biosimilars in China?